8 November 2021
The University of Oxford and Brazilian Ministry of Health have announced a joint initiative to set up a global health and clinical research unit in Brazil led by Professor Sue Ann Clemens CBE.
27 July 2021
Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.
Delayed second dose and third doses of the Oxford-AstraZeneca vaccine lead to heightened immune response
28 June 2021
Research on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose.
13 February 2021
The University of Oxford, together with three partner sites in London, Southampton and Bristol, is to launch the first study to assess the safety and immune responses in children and young adults of the ChAdOx1 nCoV-19 coronavirus vaccine.
11 February 2021
WHO SAGE says Oxford's coronavirus vaccine is safe and likely to be efficacious in older adults, and recommends its use in this age group.
4 February 2021
The Oxford Vaccine Group is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains.
17 December 2020
Researchers from the University of Oxford have published further data from the Phase I/II clinical trials of the ChAdOx1 nCoV-19 coronavirus vaccine, evidencing the decision to move to a two-dose regimen in ongoing phase III trials, and how ChAdOx1 nCov-19 induces broad antibody and T cell functions.
1 July 2020
Participants in South Africa’s first clinical trial for a vaccine against COVID-19 are to be vaccinated this week.
AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s vaccine at no profit
15 June 2020
AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine, with deliveries starting by the end of 2020.
22 May 2020
Oxford Vaccine Group researchers have begun recruiting for the next phase in human trials of a COVID-19 vaccine in human volunteers.
18 May 2020
The Government has announced £65.5 million of new funding for the vaccine being developed at the Oxford Vaccine Group as coronavirus vaccine trials accelerate.
30 April 2020
The University of Oxford has today announced an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being trialled by the Oxford Vaccine Group.
24 April 2020
University of Oxford researchers have begun testing a COVID-19 vaccine in human volunteers in Oxford today. Around 1,110 people will take part in the trial, half receiving the vaccine and the other half (the control group) receiving a widely available meningitis vaccine.
Paediatrics project receives funding to assess novel coronavirus infection rates in children and teenagers across the UK
20 April 2020
A multi-site project, called ‘What’s the STORY?’ has received funding from UK Research and Innovation (UKRI) to assess novel coronavirus infection rates in children and teenagers across the UK. Given the importance of this study to the national Covid-19 response it has been deemed a priority study for the National Institute for Health Research’s (NIHR) Urgent Public Health Response.
Funding for new COVID-19 studies awarded to OVG's project on infectious disease immunity in children
17 April 2020
Five projects from across Oxford University's Medical Sciences Division, including a project led by Professor Matthew Snape from the Oxford Vaccine Group, are among twenty-one new studies into the novel coronavirus which have been funded by the UK government.
27 March 2020
University of Oxford researchers working in an unprecedented vaccine development effort to prevent COVID-19 have started screening healthy volunteers (aged 18-55) today for their upcoming ChAdOx1 nCoV-19 vaccine trial in the Thames Valley Region. The vaccine based on an adenovirus vaccine vector and the SARS-CoV-2 spike protein is already in production but won’t be ready for some weeks still.